



Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Alexander Ian SMITH *et al.* Confirmation No.: 5599

Application No.: 10/520,624

Group Art Unit: *To Be Assigned*

Filed: January 27, 2006

Examiner: *To Be Assigned*

For: Method for Detection of Bioactive Peptides

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,
Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97
and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, copies of documents 1-7 cited in the attached Form PTO-1449 are enclosed.
- ☐ Copies of the remaining publications listed on the attached Form PTO-1449 are not being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial Nos.:
to which the above-identified application claims priority under 35 U.S.C. §120.
- ☐ Copies of documents that were not submitted in the above-mentioned related United States Patent Applications may be found in related United States Patent Application Nos.:
Should the Examiner be unable to locate a document, a copy will be provided upon request.
- ☐ No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO-1449 are being provided pursuant to 37 C.F.R. §1.98.

This Information Disclosure Statement is filed within any one of the following time periods:

- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in this international application;
- ☒ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Forms PTO-1449 to the undersigned. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-1283.

Dated: May 29, 2007

COOLEY GODWARD KRONISH LLP
ATTN: Patent Group
1200 19th Street, NW, 5th Floor
Washington, DC 20036
Tel: (202) 842-7800
Fax: (202) 842-7899

Respectfully submitted,
COOLEY GODWARD KRONISH LLP

By:



Thomas A. Blinka
Reg. No. 44,541

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. DAVI-001/00US		Application No. 10/520,624	
PTO Form 1449				Applicants: Alexander Ian SMITH <i>et al.</i>			PAGE 1 of 1
				Filing Date: January 27, 2006		Group Art Unit: <i>To Be Assigned</i>	
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
	1.	WO 00/63694 A1	10/26/2000	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	2.	Abel et al., "Modern methods to produce natural-product libraries," Curr. Opin. Chem. Biol. 6:453-458 (2002)					
	3.	Fujita et al., "Isolation and Characterization of Ovokinin, a Bradykinin B1 Agonist Peptide Derived From Ovalbumin," Peptides 16:785-790 (1995)					
	4.	Jankowski et al., "Mass-Spectrometry-Linked Screening of Protein Fractions for Enzymatic Activities – A Tool for Functional Genomics," Anal. Biochem. 290:324-329 (2001)					
	5.	Meisel, "Multifunctional peptides encrypted in milk proteins," Biofactors 21:55-61 (2004)					
	6.	Morena de Vega, "Supplementary Partial European Search Report," 5 pages, from European Patent Application No. 03735191.3, European Patent Office, Munich, Germany (dated July 24, 2006)					
	7.	Yates, III, "Mass spectrometry from genomics to proteomics," Trends in Genetics 16:5-8 (2000)					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							